<div><div></div><div><span><p><strong><span>Serina named Srini Tenjarla as Chief Technology Officer at its Serina (AL) subsidiary and increased CEO Steve Ledger's annual base salary to $500,000.</span></strong></p><div><table><tbody><tr><td><span>Individual</span></td><td><span>Srini Tenjarla, Ph.D.</span></td><td><span>Steve Ledger</span></td></tr><tr><td><span>Role</span></td><td><span>Chief Technology Officer (Serina (AL) subsidiary)</span></td><td><span>Chief Executive Officer</span></td></tr><tr><td><span>Type of Change</span></td><td><span>Appointed / Promoted</span></td><td><span>Compensation Increase</span></td></tr><tr><td><span>Effective Date</span></td><td><span>April 20, 2026 (salary increase effective March 15, 2026)</span></td><td><span>April 15, 2026 (salary increase effective September 9, 2024)</span></td></tr><tr><td><span>Reason</span></td><td><span>Promotion from Senior Vice President of CMC and Formulation</span></td><td><span>Increase pursuant to employment agreement upon satisfaction of certain strategic goals</span></td></tr><tr><td><span>Replacement Info</span></td><td><span>Not disclosed</span></td><td><span>Not disclosed</span></td></tr><tr><td><span>Background Details</span></td><td><span>Previously Senior Vice President of CMC and Formulation at Serina (AL) since July 2024</span></td><td><span>Increase followed terms of employment agreement; retroactive portion paid in lump sum April 2026</span></td></tr><tr><td><span>Board/Committee Role Changes</span></td><td><span>Not disclosed</span></td><td><span>Not disclosed</span></td></tr></tbody></table></div><p><span>Original SEC Filing: </span>Serina Therapeutics, Inc. [ SER ] - 8-K - Apr. 21, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

<p>Serina has appointed Srini Tenjarla as Chief Technology Officer of its Serina (AL) subsidiary, effective April 20, 2026. Additionally, CEO Steve Ledger's annual base salary has been increased to $500,000, effective March 15, 2026. Tenjarla was previously the Senior Vice President of CMC and Formulation at Serina (AL) since July 2024. The salary increase for Ledger is in accordance with his employment agreement, contingent upon meeting specific strategic goals.</p>

TradingView

Serina Therapeutics

iShares Global Healthcare

iShares US Pharma

Invesco Biotechnology & Genome ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

SPDR S&P Biotech

Serina names Srini Tenjarla CTO; raises CEO Steve Ledger's salary